J&J Exec Expects Lower Innovative Medicines Sales Growth In H2 2024 Due To Stelara Biosimilars Entry In Europe; No Future COVID-19 Vaccine Sales Anticipated Despite Q2 Sales
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson (J&J) anticipates lower sales growth for its innovative medicines in the second half of 2024 due to the entry of Stelara biosimilars in Europe. Additionally, J&J does not expect any future sales from its COVID-19 vaccine despite Q2 sales.
July 17, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Johnson & Johnson expects a decline in sales growth for its innovative medicines in the second half of 2024 due to the introduction of Stelara biosimilars in Europe. Additionally, the company does not foresee any future sales from its COVID-19 vaccine.
The entry of Stelara biosimilars in Europe is likely to reduce J&J's market share and revenue from this product. Additionally, the lack of future COVID-19 vaccine sales removes a potential revenue stream, negatively impacting overall sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100